Inqanaba lokuQala loNyango loMhlaza weMiphunga ngo-2026: IiNdlela zokuKhetha zaseTshayina kunye neendleko – izibhedlele ezikufutshane nam 

Inqanaba lokuqala lonyango lomhlaza wemiphunga ngo-2026 ligxile kungenelelo lonyango, ikakhulu utyando okanye i-stereotactic ablative radiotherapy (SABR), ehlala iphuculwa ngonyango lwe-perioperative immunotherapy kwizigulana ezifanelekileyo. E-China, izibhedlele ezikhokelayo ngoku zisebenzisa inkqubo ye-AJCC ye-9th edition staging kwaye zibonelela ngeendlela eziphuculweyo ezincinci, kunye neendleko ezihluka kakhulu phakathi kwamacandelo karhulumente kunye nabucala ngokusekelwe kubunzima bokunyamekela kunye neemfuno zokuvavanya i-molecular.

Ukuqonda iNqanaba lokuQala loNyango loMhlaza wemiphunga ngo-2026

Imbonakalo yomhlaba ye inqanaba lokuqala unyango lomhlaza wemiphunga iye yavela ngokumangalisayo ngo-2026, isuka kwindlela yotyando ukuya kwisicwangciso somntu ophezulu, i-multimodal. Umhlaza wemiphunga weseli ongeyonxalenye encinci (NSCLC), ngokukodwa amanqanaba I ukuya kwi-IIIB, ngoku ijongwa ngelensi yeyeza elichanekileyo. Eyona njongo iphambili ihlala iphelele ekususweni kwethumba, kodwa iindlela zokufezekisa oku kunye nonyango oluxhasayo olujikeleze utyando luye lwaba lukhuni ngakumbi.

Izikhokelo zangoku zigxininisa ukubaluleka kweqonga elichanekileyo phambi kwalo naluphi na ungenelelo. Ukwamkelwa kwenkqubo yeqonga ye-AJCC ye-9th ye-TNM iye yacokisa indlela amathumba ahlelwa ngayo, iqinisekisa ukuba izigulane zifumana unyango olufanelekileyo kumthwalo wazo wesifo esithile. Oku kuchanekileyo kubalulekile kuba nakwinqanaba lokuqala, kukho umahluko omkhulu kubungakanani bethumba kunye nokubandakanyeka kwe-lymph node eyalela indlela yonyango.

Kwizigulane ezininzi, uhambo luqala ngoxilongo oluqinisekileyo olulandelwa luvavanyo olubanzi lwebhayoloji yophawu. Eli nyathelo alisakhethi; ngumgangatho wenyameko. Uvavanyo lwe-EGFR, ALK, kunye ne-PD-L1 intetho inceda i-oncologists ukuba ibone ukuba isigulane sinokuzuza kunyango olujoliswe kuyo okanye i-immunotherapy, ngaphambi okanye emva kokuhlinzwa. Le ndlela yokusetyenziswa kwedatha iqinisekisa ukuba inqanaba lokuqala unyango lomhlaza wemiphunga ayisiyiyo iprothokholi enobungakanani obunye kodwa sisicwangciso esilungiselelwe ukukhulisa ukusinda kunye nokunciphisa ukuphindaphinda.

Indima yoLwando oluHlangeneyo kancinci

Utyando luhlala lusisiseko senjongo yonyango yenqanaba lokuqala le-NSCLC. Nangona kunjalo, iindlela zotyando ezisetyenziswe ngo-2026 ubukhulu becala ziye zasuka kwi-thoracotomy yemveli evulekileyo. Umgangatho wangoku wokhathalelo ucebisa ngamandla iindlela ezincinci zokungena kwizigulane ngaphandle kokuchasana kwe-anatomical.

• Utyando lweThoracoscopic oluNceda ngeVidiyo (VATS): Obu buchule busebenzisa amanxeba amancinci kunye nekhamera ukususa ithumba. Inxulunyaniswa neentlungu ezincinci, ukuhlala ixesha elifutshane esibhedlele, kunye namaxesha okubuyisela ngokukhawuleza xa kuthelekiswa notyando oluvulekileyo.
• Uqhaqho oluNcedwa ngeRobhothi: Ifumaneka ngakumbi kwizibhedlele zaseTshayina ezikumgangatho ophezulu, iinkqubo zerobhothi zibonelela ngoogqirha botyando ngobuchule obuphuculweyo kunye nokubonwa kwe-3D. Oku kuvumela i-lymph node dissection echanekileyo kunye ne-resections eyinkimbinkimbi ngaphambili eyayinzima ukuyenza ngokuncinci.

Ukhetho phakathi kwe-VATS kunye notyando lwerobhothi kaninzi luxhomekeke kubuchule bogqirha wotyando kunye neempawu ezithile zethumba. Kwimibhobho ye-peripheral engaphantsi kwe-3 yeesentimitha ene-negative lymph nodes ye-mediastinal, ezi ndlela zokuhlaselwa kancinci ngowona mgca wokuqala wokuzikhusela. Injongo ihlala i-R0 resection, oku kuthetha ukususwa ngokupheleleyo kwe-tumor kunye nemida ecacileyo.

I-Stereotactic Abblative Radiotherapy njengenye indlela

Ayisiso sonke isigulana esinomhlaza wemiphunga wenqanaba lokuqala umntu oza kutyandwa. Izinto ezifana nokwaluphala, ukungasebenzi kakuhle kwemiphunga, okanye iingxaki ezibalulekileyo ezinokuthi zenze imingcipheko yotyando ingamkeleki. Kwaba bantu, I-stereotactic ablative radiotherapy (SABR), ekwaziwa njenge-SBRT, iye yavela njengenye indlela esebenza kakhulu.

I-SABR ihambisa iidosi eziphezulu zemitha ngokuchaneka okugqithisileyo kwithumba ngelixa igcina izicubu ezisempilweni ezingqongileyo. Idatha yakutsha nje icebisa ukuba kwizigulana ezikwinqanaba lakwangoko elingasebenziyo ngokwezonyango, i-SABR inokubonelela ngamazinga olawulo lwasekhaya athelekiswa notyando. Ngo-2026, izikhokelo zeklinikhi zixhasa inkqubo yokwenza izigqibo ekwabelwana ngazo apho izigulane zixelelwa ukuba i-SABR lukhetho olunokunyangeka ukuba utyando alunakwenzeka.

Ngaphaya koko, kwezinye izigulana ezisebenza ngobuchwephesha kodwa zikhetha ukuluphepha utyando, i-SABR iya ixoxiwa ngakumbi njengenye indlela emva kokucetyiswa ngokucokisekileyo. Itekhnoloji esemva kwe-SABR iphucukile, ivumela ulawulo olungcono lwentshukumo kunye nokupeyintwa kwethamo, okwandisa ukusebenza kwayo ngokuchasene namathumba emiphunga ashukumayo.

I-Perioperative Immunotherapy: Impumelelo enkulu ngo-2026

Enye yezona nkqubela zibalulekileyo kwi inqanaba lokuqala unyango lomhlaza wemiphunga kwiminyaka yakutshanje kukuhlanganiswa kwe-immunotherapy kwisimo se-perioperative. Ngokwembali, ichemotherapy yayilunyango oluqhelekileyo lwe-adjuvant emva kotyando kwizigulana ezikwinqanaba lokuqala. Nangona kunjalo, i-paradigm itshintshile ngokungeniswa kwe-immune checkpoint inhibitors njenge-pembrolizumab.

Uphononongo lwe-KEYNOTE-671 lube ngundoqo ekumiseni ngokutsha iiprothokholi zonyango. Olu lingo lubalulekileyo lubonise ukuba ukunika i-pembrolizumab phambi kotyando (neoadjuvant) nasemva kotyando (adjuvant), kudityaniswe nechemotherapy, kuphucula kakhulu ukusinda ngaphandle kwesiganeko. Ngo-2026, idatha yexesha elide evela kolu phononongo, kunye neenyanga ezingaphezu kwe-60 yokulandelelana, iqinise indima yale ndlela.

Izibonelelo kungakhathaliseki ukuba yi-Pathological Complete Response

Ukufunyaniswa okubalulekileyo kuhlalutyo lwamva nje lwe-KEYNOTE-671 yolingo kukuba izigulana ziyazuza kunyango lwe-perioperative immunotherapy nokuba bayayifeza impendulo epheleleyo ye-pathological (pCR). I-pCR ibhekisa kukungabikho kweeseli zethumba elisebenzayo kumzekelo wotyando emva konyango lwe-neoadjuvant.

• pCR Abemi: Izigulana eziphumelele i-pCR zibonise ukwehla okumangalisayo kumngcipheko wokuqhubela phambili kwesifo okanye ukufa, kunye nomlinganiselo wengozi othanda kakhulu iqela le-immunotherapy.
• Non-pCR Abemi: Okubalulekileyo kukuba, nezigulana ezingazange ziyifezekise i-pCR zisafumana inzuzo enkulu yokusinda. Umlinganiselo weengozi weli qela ubonise ukwehla okunentsingiselo kumngcipheko xa kuthelekiswa nabo bafumana ichemotherapy kuphela.

Le datha ibonisa ukuba ukusebenza kwe-immune system kunika umphumo okhuselekileyo wokukhusela odlula ngaphaya kokunciphisa ngokukhawuleza kwe-tumor. Kuthetha ukuba iimpendulo "ezinzulu" ze-pathological zihambelana neziphumo ezingcono, kodwa naliphi na inqanaba lokuzibandakanya komzimba kunenzuzo. Ngenxa yoko, ii-oncologists e-China nakwihlabathi jikelele ngoku zihlala zivavanya inqanaba le-II ne-IIA labaguli abafanelekileyo kule ndlela yokudibanisa edibeneyo.

Ukwandiswa ukuya kuManqanaba angaphambili

Ngelixa impumelelo yokuqala yabonwa kwinqanaba le-II kunye ne-III isifo, impumelelo ye-perioperative immunotherapy ikhuthaza uphando malunga nokusetyenziswa kwayo kwizigulane ezikhethiweyo eziphezulu ze-I. Nangona isifo senqanaba le-IA esiqhelekileyo sinyangwa ngotyando lodwa, amathumba e-IB amakhulu okanye lawo aneempawu zomngcipheko ophezulu aqwalaselwe izicwangciso ze-neoadjuvant kulingo lwezonyango nakumaziko awodwa.

Ingqiqo kukunyanga isifo se-micrometastatic kwangoko, ngaphambi kokuba i-tumor isuswe, ngaloo ndlela inciphisa ithuba lokuphindaphinda. Esi simo sokusebenza simela utshintsho olusisiseko kwindlela esiwujonga ngayo umhlaza wemiphunga wenqanaba lokuqala-hayi nje njengengxaki yendawo ekufuneka inqunyulwe, kodwa njengesifo senkqubo esifuna ulawulo lwenkqubo kwasekuqaleni.

Izibhedlele eziKhokelayo zaseTshayina zoNonophelo loMhlaza weLung

Xa ufuna inqanaba lokuqala unyango lomhlaza wemiphunga eTshayina, abaguli banokufikelela kwamanye amaziko ezonyango aphambili ehlabathini. Ilizwe lenze amanyathelo abalulekileyo ekubekeni ukhathalelo olusemgangathweni kunye nokwamkela izikhokelo zamazwe ngamazwe ngelixa lisebenzisa umthamo walo omkhulu wezigulane ukuqhuba uphando kunye nokutsha.

Ukukhetha isibhedlele esifanelekileyo kubalulekile. Amaziko aphezulu abonakaliswe ngamaqela awo ahlukeneyo (i-MDT), abandakanya oogqirha be-thoracic, i-oncologists yezonyango, i-oncologists ye-radiation, i-radiologists, kunye nee-pathologists ezisebenza kunye ukwenza isicwangciso esingcono kwisigulane ngasinye. La maziko nawo ahamba phambili ekuphumezeni i-AJCC 9th edition staging kunye nokuqhuba uvavanyo oluyimfuneko lwe-molecular.

Tianjin Medical University Cancer Institute kunye nesibhedlele

Ifumaneka eTianjin, eli ziko liyinkokeli yelizwe kwi-oncology. Ngaphantsi kwesikhokelo seengcali ezifana noNjingalwazi You Jian, isibhedlele siye saba negalelo ekutolikeni nasekusebenziseni idatha evela kwiimvavanyo ezinkulu zamazwe ngamazwe njenge-KEYNOTE-671. Isebe labo lotyando lwe-thoracic lidume ngeenkqubo ezisezantsi zomthamo omncinci kunye neeprothokholi ezomeleleyo zokhathalelo lweperioperative.

Isibhedlele sigxininisa ukubaluleka kovavanyo lwe-pathological and profiling molecular. Baye baseka ukuhamba komsebenzi okungqongqo ukuqinisekisa ukuba sonke isigulana se-NSCLC esihlanjululwayo siyavavanywa ukuze sifumane uncedo olunokubakho lwe-immunotherapy. Igalelo labo lophando linceda ukuchaza umgangatho wokhathalelo hayi eTshayina kuphela, kodwa kwiAsia iphela.

Isibhedlele saBantu sePhondo laseZhejiang kunye nesibhedlele somhlaza saseZhejiang

E-Hangzhou, isibhedlele somhlaza saseZhejiang, esikhokelwa ziingcali ezinjengoNjingalwazi uXu Yujin, sesinye isixhobo esinamandla kunyango lomhlaza wemiphunga. Isibhedlele saziwa ngokudityaniswa kwetekhnoloji yokusika ekuxilongeni nasekunyangweni. Bathatha inxaxheba ngokukhutheleyo kulingo lwezonyango lwehlabathi, benika izigulane ukufikelela kunyango olutsha phambi kokuba lufumaneke ngokubanzi.

Indlela yabo yokufikelela kwinqanaba lokuqala lomhlaza wemiphunga ibandakanya ukucwangciswa kwangaphambili konyango, kubandakanya nenqanaba le-mediastinal elihlaselayo xa kuyimfuneko. Basebenzisa ubuchule bokucinga obuphezulu kunye ne-AI-aid diagnostics ukufumanisa ukubandakanyeka okufihlakeleyo kwe-nodal enokuthi iphoswe kwenye indawo, ukuqinisekisa ukuba isicwangciso sonyango sihambelana ngokugqibeleleyo nesigaba sesifo.

Isibhedlele sokuqala esiManyaniswe neYunivesithi yaseSun Yat-sen

Ngokusekwe e-Guangzhou, esi sibhedlele sibonelela ngokhathalelo olubanzi ngokugxininisa ngamandla kwizicwangciso zonyango lomntu ngamnye. Unjingalwazi uCheng Chao kunye neqela lakhe bazinikele ekwandiseni ukulandelelana konyango. Banobuchule obukhethekileyo bokulawula iimeko ezintsonkothileyo apho ukugula kunokwenza nzima iindlela zonyango ezisemgangathweni.

Iziko ligxininisa kakhulu kwimfundo yezigulane kunye nokwenza izigqibo ekwabelwana ngazo. Baqinisekisa ukuba izigulana ziyawaqonda ama-nuances oxilongo lwabo, ingqiqo emva kokukhetha utyando xa kuthelekiswa ne-SABR, kunye neengenelo ezinokubakho zokongeza unyango lwamajoni omzimba. Le modeli yesigulane-centric ihambelana nentsingiselo yehlabathi ngokubhekiselele kukhathalelo lwezempilo olusekelwe kwixabiso.

IiProtocol zokuxilonga kunye nokuchaneka kweStaging

Iqonga elichanekileyo sisiseko sempumelelo inqanaba lokuqala unyango lomhlaza wemiphunga. Ukungabhalwa kakuhle kunokukhokelela ekubeni unganyangeki okanye ube netyhefu engeyomfuneko. Ngo-2026, izibhedlele zaseTshayina zibambelela kwiiprothokholi zoxilongo ezingqongqo ukuqinisekisa ukuchaneka.

Ukwamkelwa kwe-AJCC 9th Edition

Ukutshintshela kwi-AJCC 9th edition ye-TNM inkqubo yeqonga izise ukuhlelwa kwegranular. Olu hlaziyo lucokisa iinkcazo zeentlobo zobungakanani bethumba kunye nezikhululo ze-lymph node. Umzekelo, umahluko phakathi kwe-T1a, T1b, kunye ne-T1c tumors ngoku ubaluleke kakhulu ekumiseleni ubungakanani botyando kunye nesidingo sonyango lwe-adjuvant.

Izibhedlele zaseTshayina zihlaziye iinkqubo zazo zokunika ingxelo ukuze zihambelane nale migangatho mitsha. Oku kuqinisekisa ukuhambelana kunxibelelwano phakathi kweeklinikhi kunye nokuququzelela ukubhaliswa ngokuchanekileyo kwizilingo zeklinikhi. Ikwavumela uqikelelo olungcono lwe-prognostic, ukunceda izigulane kunye noogqirha babeke izinto ezilindelekileyo.

Uvavanyo olunyanzelekileyo lweMolekyuli yeBiomarker

Zihambile iintsuku xa uvavanyo lwe-biomarker lwalugcinelwe isifo esikwinqanaba eliphezulu. Izikhokelo zangoku zigunyazisa ukuba zonke izigulane ezine-NSCLC ezihlanjululwayo zivavanyelwe abaqhubi abaphambili. Oku kubandakanya ukuguqulwa kwe-EGFR, ukulungiswa kwakhona kwe-ALK, kunye namanqanaba okuchaza i-PD-L1.

• I-EGFR kunye ne-ALK: Ukuchonga olu tshintsho lubalulekile kuba lunokuchaphazela ukhetho lonyango lwe-adjuvant. Izigulane ezinokuguqulwa kwe-EGFR, umzekelo, zinokuzuza kwi-target target ye-tyrosine kinase inhibitors (TKIs) emva kokuhlinzwa.
• PD-L1: Inqanaba lenkcazo ye-PD-L1 inceda ukuqikelela amathuba okuphendula kwi-immunotherapy. Ngelixa i-perioperative pembrolizumab ivunyiwe kungakhathaliseki ukuba yiyiphi i-PD-L1 imeko kwezinye iimeko, ukwazi izibonelelo zesimo kuhlalutyo lwenzuzo-yenzuzo.

Olu vavanyo lubanzi ngoku luyinto yesiqhelo kwizibhedlele eziphezulu zaseTshayina. Ixesha lokuguqula iziphumo lehlile ngenxa yokuphuculwa kweziseko ezingundoqo zelebhu, evumela unyango ukuba luqale ngaphandle kolibaziseko olungeyomfuneko.

I-Invasive Mediastinal Staging

Ukucinga yedwa ngamanye amaxesha akwanelanga ukulawula i-lymph node metastasis. Uninzi lwezigulane zesigaba se-I kunye ne-II, ngakumbi abo banamathumba asembindini okanye iindawo ezikrokrelayo kwi-CT / PET scans, i-invasive staging ye-mediastinal iyacetyiswa ngaphambi kokuhlinzwa.

Iindlela ezifana ne-Endobronchial Ultrasound (EBUS) kunye ne-Endoscopic Ultrasound (EUS) zisetyenziswa ngokubanzi. Ezi nkqubo zohlaselo zincinci zivumela i-biopsy yexesha lokwenyani ye-mediastinal lymph nodes. Ukuba isifo se-N2 siqinisekisiwe, isicwangciso sonyango sitshintsha ukusuka kunyango lwangaphambili ukuya kunyango lwe-neoadjuvant, ngokusisiseko sitshintsha umkhondo wesigulane.

Uhlalutyo lweendleko kunye ne-Inshurensi ye-Inshurensi e-China

Ukuqonda umba wemali inqanaba lokuqala unyango lomhlaza wemiphunga ibalulekile kwizigulana ezicwangcisa ukhathalelo lwazo eTshayina. Iindleko zinokwahluka ngokubanzi ngokuxhomekeke kwinqanaba lesibhedlele, unyango oluthile olufunekayo, kunye nemeko yeinshorensi yomguli.

Ukwahlulwa kweendleko zonyango

Ixabiso lilonke lonyango libandakanya amacandelo amaninzi: ukuxilonga, utyando okanye ngemitha, i-pathology, uvavanyo lwemolekyuli, kunye naluphi na unyango lwenkqubo.

• Uxilongo kunye nenqanaba: Ukubonisana kokuqala, i-CT scans, i-PET-CT, kunye ne-MRI yobuchopho inokuqala ukusuka kumawaka ambalwa ukuya kwi-RMB yamawaka alishumi. Iinkqubo zeqonga ezihlaselayo ezifana ne-EBUS zongeza kule ndleko.
• Utyando: Utyando olungephi (i-VATS okanye i-robotic) luxabisa ngaphezulu kunotyando oluvulelekileyo ngenxa yezixhobo kunye nezakhono ezikhethekileyo ezifunekayo. Utyando lwerobhothi, ngokukodwa, lunokubiza kakhulu, ludla ngokugqitha kwi-50,000 ukuya kwi-80,000 RMB ngokuxhomekeke kububunzima.
• Unyango ngeRadio: Ikhosi ye-SABR lutyalo-mali olukhulu, olunokuxabisa phakathi kwe-30,000 kunye ne-60,000 RMB, ebonisa ubugcisa obuphambili kunye nocwangciso olubandakanyekayo.
• Unyango Lwenkqubo: Iindleko zonyango ngamachiza zimodareyitha xa kuthelekiswa, ngakumbi xa kunokwenziwa amayeza enziwe afana nalawo enziwe ngabenzi. Nangona kunjalo, iiarhente ze-immunotherapy ezifana ne-pembrolizumab zinokubiza. Ngelixa amaxabiso ehlile ngenxa yothethathethwano lwesizwe, inkqubo epheleleyo yonyango lweperioperative isenokufikelela kumashumi amawaka e-RMB.

Imigaqo-nkqubo yokuBuyiselwa kwe-inshorensi

Inkqubo ye-inshurensi yonyango esisiseko yaseTshayina iquka inxalenye ebalulekileyo yonyango oluqhelekileyo. Utyando, ichemotherapy eqhelekileyo, kunye nesiseko seradiotherapy zigqunywe kakuhle. Nangona kunjalo, ukhuseleko kunyango olutsha olufana nonyango lwe-immunotherapy kunye notyando lwerobhothi luyahluka ngokwengingqi kunye nesicwangciso esithile se-inshurensi.

Kwiminyaka yakutshanje, amachiza amaninzi amatsha, kuqukwa ne-immunotherapies engundoqo, afakwe kuLuhlu lweZiyobisi lwembuyekezo yeSizwe (NRDL). Oku kunciphise kakhulu iindleko eziphuma epokothweni kwizigulana. Umzekelo, i-pembrolizumab kunye nezinye ii-PD-1 inhibitors ngoku zibuyiselwa ngokuyinxenye kwiimpawu ezithile, zizenza zifikeleleke kuluntu olubanzi.

Izigulane zicetyiswa ukuba ziqhagamshelane neofisi ye-inshurensi yesibhedlele kwangethuba kwinkqubo. Ezinye izibhedlele zikwabonelela ngentsebenziswano ye-inshurensi yorhwebo okanye iinkqubo zoncedo lwesisa ukunceda ukuvala umsantsa wonyango olubiza imali eninzi olungahlawulwanga ngokupheleleyo yi-inshurensi esisiseko.

ISikhokelo seNyathelo ngeNyathelo sokuHamba kuNyango eTshayina

Kwizigulane zamazwe ngamazwe okanye zasekhaya ezifuna ukhathalelo, ukuhamba ngenkqubo yokhathalelo lwezempilo kunokuba nzima. Indlela ecwangcisiweyo iqinisekisa ukuba akukho manyathelo abalulekileyo alahlekileyo kwaye isigulane sifumana eyona nto ifanelekileyo inqanaba lokuqala unyango lomhlaza wemiphunga.

• Inyathelo 1: Uluvo lweSibini kunye nokuRekhoda kwakhona: Phambi kokuba uzibophelele kwisicwangciso sonyango, fumana uluvo lwesibini. Izibhedlele ezininzi eziphezulu zibonelela ngeenkonzo zokubonisana ezikude apho iingcali ziphonononga ingxelo ekhoyo ye-imaging kunye ne-pathology. Oku kuqinisekisa ukuxilongwa kunye nokuchaneka kwezigaba.
• Inyathelo 2: Uvavanyo oluBanzi lweBiomarker: Qinisekisa ukuba iisampulu zethishu zithunyelwa ukuze kujongwe iprofayili yemolekyuli epheleleyo. Ukuba imathiriyeli yokuqala ye-biopsy ayonelanga, kungafuneka uphinda-phindo lwe-biopsy. Musa ukuqhubela phambili kunyango oluqinisekileyo ngaphandle kwezi ziphumo.
• INyathelo 3: Iingxoxo zeqela leeNgxoxo ezininzi (MDT): Cela intlanganiso ye-MDT. Oku kuqinisekisa ukuba oogqirha botyando, ii-oncologists, kunye nee-radiologists ziyavumelana ngokulandelelana konyango. Buza ngokuthe ngqo malunga nokufaneleka kwe-perioperative immunotherapy.
• Inyathelo lesi-4: UCwangciso loTyando okanye lweRadiation: Ukuba utyando lukhethiwe, xubusha indlela (VATS vs. Robotic). Ukuba i-SABR ikhethiwe, qinisekisa amava kunye nobuchwepheshe beziko. Qinisekisa ixesha lokuqaliswa konyango.
• Inyathelo lesi-5: Uvavanyo lwasemva koNyango: Misela ishedyuli ecacileyo yokulandelela. Ukufunyaniswa kwangoko kokuvela kwakhona kubalulekile. Oku kubandakanya ii-CT scans rhoqo kunye novavanyo lweklinikhi ubuncinci iminyaka emihlanu.

Ukulandela la manyathelo kuxhobisa izigulane ukuba zithathe inxaxheba ebonakalayo ekukhathaleni kwazo. Ikwaqinisekisa ulungelelwaniso kunye nezikhokelo zamva nje zika-2026, ukwandisa amathuba okunyanga.

Uhlalutyo lokuthelekisa kwiiNdlela zoNyango

Ukunceda izigulana kunye neentsapho ziqonde iinketho zabo, le theyibhile ilandelayo ithelekisa iindlela zonyango ezisisiseko ezikhoyo kwinqanaba lokuqala lomhlaza wemiphunga ngo-2026.

Olu thelekiso lubonisa ukuba ngelixa utyando luhlala luyindlela ephambili yokunyanga, umxholo ohanjiswa kuwo utshintshile. Ukongezwa konyango olucwangcisiweyo kunye nokufumaneka kwezinye iindlela zomgangatho ophezulu wokusasazeka kwemitha zibonelela ngomnatha wokhuseleko kwiimfuno ezahlukeneyo zezigulane.

Iindlela zexesha elizayo kunye nobuGcisa obusakhulayo

Ukujonga ngaphaya kuka-2026, intsimi yonyango lomhlaza wemiphunga iyaqhubeka nokwenza izinto ezintsha. Iindlela ezininzi ezivelayo zikulungele ukucokisa ngakumbi inqanaba lokuqala unyango lomhlaza wemiphunga kunye nokuphucula iziphumo.

Intelligence Artificial in Diagnosis

Ii-algorithms ze-AI ziba yinto ebalulekileyo kuhambo lokuxilonga. Ezi zixhobo zinokuhlalutya i-CT scans ngokuchaneka okungaphaya kobuntu, ukubona amaqhuqhuva afihlakeleyo kunye nophawu lwe-lymph nodes anokuthi awaphose amehlo abantu. E-China, i-“China Protocol” yokuhlola umhlaza wemiphunga isebenzisa i-AI ukunyusa izinga lokubhaqwa kwangethuba, ityhala inqanaba lenqanaba lokuxilonga liphezulu.

I-AI ikwancedisa ekucwangcisweni kwonyango ngokuqikelela ukuba zeziphi izigulane ezinokuthi ziphendule kunyango oluthile. Lo buchule bokuxela kwangaphambili busondeza iyeza kubuntu bokwenyani, kucutha ulingo-kunye-nempazamo emiselweyo.

I-Liquid Biopsy yokuHlola

Uvavanyo olujikelezayo lwe-tumor DNA (ctDNA), okanye i-biopsy engamanzi, ifumana ukutsalwa njengesixhobo sokujonga impendulo yonyango kunye nokufumanisa isifo esishiyekileyo (MRD). Emva kotyando, uvavanyo oluqinisekileyo lwe-ctDNA lunokubonisa iiseli zomhlaza eziseleyo, nto leyo ebangela ungenelelo lwangaphambili ngonyango lwe-adjuvant.

Le ndlela engabonakaliyo inikezela ngombono oguqukayo wesimo sesifo, okuvumela oogqirha ukuba bahlengahlengise izicwangciso zonyango ngexesha langempela. Njengoko itekhnoloji isiya iba novakalelo ngakumbi kwaye ifikeleleka, kulindeleke ukuba ibe yinxalenye eqhelekileyo yokucupha emva kokusebenza.

Gxininisa ekuSindeni kunye noMgangatho woBomi

Njengoko amazinga okusinda ephucuka, ingqwalasela itshintshela kumgangatho wobomi bamaxhoba. Iinkqubo ezijongene nokugcinwa kokuchuma, ukujongwa kwempilo yentliziyo, kunye nenkxaso yengqondo zidityaniswa kwizicwangciso zonyango. Ziqonda ukuba umhlaza usiba yimeko elawulekayo engapheliyo kwabaninzi, izibhedlele zisebenzisa indlela epheleleyo yokhathalelo.

Olu tshintsho luyavuma ukuba ukunyanga isifo yinxalenye nje yobuthunywa; ukunceda izigulane zibuyele kubomi obanelisayo kubaluleke ngokulinganayo. Iinkonzo zokunakekelwa kwenkxaso ziyanda ukuhlangabezana neemfuno ze "sandwich generation" yezigulane ezilinganisa unyango kunye nomsebenzi kunye noxanduva lwentsapho.

Imibuzo Ebuzwa Rhoqo malunga nenqanaba lokuQala loNyango loMhlaza weMiphunga

Ingaba isigaba sokuqala somhlaza wemiphunga siyanyangeka?

Ewe, inqanaba lokuqala lomhlaza wemiphunga linyangeka kakhulu. Ngonyango olufanelekileyo, olunjengotyando okanye i-SABR, izinga leminyaka emihlanu lokusinda kwisigaba se-IA sesifo sinokudlula i-90%. Undoqo kukubona kwangoko kunye nokubambelela kwiiprothokholi zonyango ezisemgangathweni.

Ingaba unyango luthatha ixesha elingakanani?

Ubude bexesha buyohluka ngokweendlela. Utyando lubandakanya ukuhlala esibhedlele kwiintsuku ezi-3 ukuya kwezi-7, kunye nokuchacha ngokupheleleyo kuthatha iiveki ezimbalwa ukuya kwiinyanga. Ukuba i-perioperative immunotherapy yongezwa, yonke ikhosi yonyango, kubandakanywa nezigaba zangaphambili kunye nezasemva kokuhlinzwa, zinokuthatha iinyanga ezi-6 ukuya kwezi-12. I-SABR idla ngokugqitywa kwiseshoni e-1 ukuya kwezi-5 kwiveki okanye ezimbini.

Ngaba ndingalufumana unyango lwe-immunotherapy kwinqanaba lokuqala lomhlaza wemiphunga?

Okwangoku, unyango lwe-perioperative immunotherapy lusemgangathweni wenqanaba le-II kunye ne-IIA elihlaziywayo le-NSCLC. Kwinqanaba elimsulwa lesifo I, asibonakalisi ngaphandle kokuba kukho iimpawu zomngcipheko ophezulu okanye ubhaliso kulingo lwezonyango. Nangona kunjalo, izikhokelo zivela ngokukhawuleza, ngoko ke ukuxoxa ngemeko yakho kunye ne-oncologist kubalulekile.

Zeziphi iziphumo ebezingalindelekanga zonyango?

Utyando luthwala imingcipheko efana nosulelo, ukopha, kunye neentlungu, nangona iindlela ezingephi zinciphisa ezi. I-Immunotherapy inokubangela iziganeko ezimbi ezinxulumene nomzimba ezichaphazela imiphunga, ulusu, okanye amathumbu. I-SABR inokubangela ukudinwa okanye ukudumba kwendawo. Uninzi lweziphumo ebezingalindelekanga ziyalawuleka ngohlolo olululo lwezonyango.

Isiphelo: Ukuthatha inyathelo leZiphumo eziNgcono

Unyaka ka-2026 uphawula ithuba elingazange libonwe ngaphambili kwizigulana ezine inqanaba lokuqala unyango lomhlaza wemiphunga. Ukuqhubela phambili kubuchule botyando, ukudityaniswa kwe-perioperative immunotherapy, kunye nokuchaneka koxilongo lwale mihla kuguqule ukuxela kwangaphambili umhlaza wemiphunga wenqanaba lokuqala. E-China, izibhedlele ezikumgangatho wehlabathi zikhokela intlawulo, zibonelela ngokhathalelo olukhuphisana nelona hlabathi libalaseleyo.

Impumelelo ekunyangeni umhlaza wemiphunga ixhomekeke kwindibaniselwano yamanyathelo angexesha, inqanaba elichanekileyo, kunye nokufikelela kubuchwephesha bezinto ezininzi. Izigulane ziyakhuthazwa ukuba zifune unyango kumaziko awodwa apho izikhokelo zamva nje zilandelwa ngokungqongqo. Nokuba kungotyando olungephi, ngemitha ephucukileyo, okanye indibaniselwano yonyango lwenkqubo, injongo icacile: unyango kunye nokubuyela kumgangatho ophezulu wobomi.

Ukuhamba kolu hambo kufuna izigqibo ezinolwazi. Ngokuqonda iinketho ezikhoyo, ukubaluleka kovavanyo lwe-biomarker, kunye neenzuzo ezinokubakho zonyango olutsha, izigulane zinokuthethelela ukhathalelo olungcono kakhulu. Ikamva lonyango lomhlaza wemiphunga liqaqambile, liqhutywa yinzululwazi kunye nokuzibophelela kukhathalelo lwexabiso olugxile kwisigulana.